Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Updated EU Guide On Safety Features Addresses Parallel Trade Repackaging

Executive Summary

The EU guideline on complying with the requirement to affix safety features on medicine packs has been updated to address specific aspects of parallel trade, such as re-sealing of medicine packs that are legally opened to replace patient information leaflets.

You may also be interested in...



Meet EU Safety Feature Deadline Or Face Penalties, Firms Warned

Pharma firms, distributors and pharmacies have been warned that they need to take action to ensure they are ready for the implementation of Europe's product verification system in February 2019. Brexit, though, has cast uncertainty over the extent of the UK's participation in the new system.

Parallel Trade Adds Up As Abacus Prepares IPO

With revenues from its parallel trade business climbing 50% year-on-year since 2015, Denmark's Abacus is to seek a listing in Germany to help it keep up with demand.

Industry ‘Deeply Concerned’ Over Slow Progress With EU Drug Authentication System

Pharmaceutical industry stakeholders are “deeply concerned” about the slow rate of sign-ups to the future European medicines authentication system, according to the industry federation EFPIA. To encourage more companies to connect as early as possible, the joining fee is to increase this month. There are also wider worries about EU member state implementation of the system.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS123460

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel